<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01370902</url>
  </required_header>
  <id_info>
    <org_study_id>NN8765-3658</org_study_id>
    <secondary_id>2010-019234-28</secondary_id>
    <secondary_id>U1111-1120-2542</secondary_id>
    <nct_id>NCT01370902</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of NNC0141-0000-0100 in Subjects With Rheumatoid Arthritis</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled, Single-dose and Multiple-dose, Dose-escalation Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0141-0000-0100 in Subjects With Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innate Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innate Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The aim of this dose-escalating trial is to assess the
      safety, tolerability, pharmacokinetics (the rate at which the body eliminates the trial drug)
      and pharmacodynamics (the effect of the investigated drug on the body) of single and repeated
      doses of NNC141-0100 in subjects with Rheumatoid Arthritis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>from trial product administration to week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antibodies against NNC141-0100</measure>
    <time_frame>from trial product administration until final visit (week 12 or longer if applicable)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time curve - SD trial part</measure>
    <time_frame>from trial product administration until final visit (week 12 or longer if applicable)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t½) - SD trial part</measure>
    <time_frame>from trial product administration until final visit (week 12 or longer if applicable)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t½) - MD trial part</measure>
    <time_frame>from trial product administration until final visit (week 12 or longer if applicable)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Inflammation</condition>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Single-dose (SD) trial part (i.v.)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Single-dose (SD) trial part (s.c.)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple-dose (MD) trial part (s.c.)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC 0141-0000-0100</intervention_name>
    <description>Single dose administered subcutaneously (under the skin), up to six dose levels. Progression to next dose will be based on safety evaluation. Initiation of the MD s.c. phase will depend on the results from the SD i.v. cohorts as well as the first two dose cohorts of the SD s.c. part</description>
    <arm_group_label>Single-dose (SD) trial part (s.c.)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Single dose administered subcutaneously (under the skin) as a comparator at all dose levels</description>
    <arm_group_label>Single-dose (SD) trial part (s.c.)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC 0141-0000-0100</intervention_name>
    <description>Multiple doses administered subcutaneously (under the skin) at 4 different occasions with a dosing interval of two weeks, at five different dose levels.</description>
    <arm_group_label>Multiple-dose (MD) trial part (s.c.)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Multiple doses administered subcutaneously (under the skin) as a comparator at all dose levels</description>
    <arm_group_label>Multiple-dose (MD) trial part (s.c.)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC 0141-0000-0100</intervention_name>
    <description>Single dose administered intravenously (into a vein), up to nine dose levels. Progression to next dose will be based on safety evaluation. Initiation of the SD s.c. phase will depend on the results from the first three dose cohorts of the SD i.v. part</description>
    <arm_group_label>Single-dose (SD) trial part (i.v.)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Single dose administered intravenously (into a vein), as a comparator at all dose levels</description>
    <arm_group_label>Single-dose (SD) trial part (i.v.)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A diagnosis of rheumatoid arthritis (RA) according to the American College of
             Rheumatology (ACR1987 classification) of at least 3 months duration prior to
             randomisation

          -  Active Rheumatoid Arthritis (RA) characterised by a DAS28-CRP (Disease Activity Score
             of 28 joints, calculated with CRP (C-reactive protein) value) greater than or equal to
             3.2

          -  Females must be post-menopausal or surgically sterile (post-menopausal for at least 1
             year) or be willing to use highly effective method of birth control

          -  Males must be willing to use highly effective contraception

          -  Subjects on stable doses of methotrexate (7.5 to 25 mg/week, both inclusive) for at
             least 4 weeks prior to randomisation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Renaud Buffet</last_name>
    <role>Study Director</role>
    <affiliation>Innate Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 31, 2011</study_first_submitted>
  <study_first_submitted_qc>June 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2011</study_first_posted>
  <last_update_submitted>December 20, 2014</last_update_submitted>
  <last_update_submitted_qc>December 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

